Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000788518 | SCV000927665 | uncertain significance | not provided | 2018-04-30 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000788518 | SCV001148819 | uncertain significance | not provided | 2019-03-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001037197 | SCV001200598 | uncertain significance | Mevalonic aciduria; Porokeratosis 3, disseminated superficial actinic type; Hyperimmunoglobulin D with periodic fever | 2024-08-12 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 292 of the MVK protein (p.Leu292Phe). This variant is present in population databases (rs145586352, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with MVK-related conditions. ClinVar contains an entry for this variant (Variation ID: 636630). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MVK protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000788518 | SCV001824785 | uncertain significance | not provided | 2020-08-13 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002535777 | SCV003754888 | uncertain significance | Inborn genetic diseases | 2022-12-01 | criteria provided, single submitter | clinical testing | The c.874C>T (p.L292F) alteration is located in exon 9 (coding exon 8) of the MVK gene. This alteration results from a C to T substitution at nucleotide position 874, causing the leucine (L) at amino acid position 292 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000788518 | SCV005408387 | uncertain significance | not provided | 2023-12-29 | criteria provided, single submitter | clinical testing | BP4, PM2_moderate |